[go: up one dir, main page]

AR055041A1 - Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. - Google Patents

Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.

Info

Publication number
AR055041A1
AR055041A1 ARP060100953A ARP060100953A AR055041A1 AR 055041 A1 AR055041 A1 AR 055041A1 AR P060100953 A ARP060100953 A AR P060100953A AR P060100953 A ARP060100953 A AR P060100953A AR 055041 A1 AR055041 A1 AR 055041A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
atoms
substituted
membered aromatic
Prior art date
Application number
ARP060100953A
Other languages
English (en)
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37023348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055041(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of AR055041A1 publication Critical patent/AR055041A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)

Abstract

Composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de formula estructural (1) y las sales, ésteres y solvatos farmacéuticamente aceptables de la misma, en los que: -------- se selecciona de un enlace simple y un enlace doble; ôAö se selecciona a partir de un grupo que consta de (a) un anillo aromático de 5 miembros que contiene (i) uno o más átomos de C, (ii) un heteroátomo seleccionado a partir de O y S, y (iii) 0, 1, 2 o 3 átomos de N; (b) un anillo aromático de 5 miembros que contiene uno o más átomos de C y de uno a cuatro átomos de N, (c) un anillo aromático de 6 miembros que contiene átomos de C y 1, 2 o 3 átomos de N; (d) un sistema anillo bicíclico seleccionado de benzotienilo, indolilo, quinolinilo y naftalenilo; (e) fenilo, y (f) -CH2-fenil; y en los que A está opcionalmente mono- o di-sustituida con un sustituyente independientemente seleccionado en cada aparicion del grupo consistente en (i) -F, (ii) -Cl, (iii) -alquilo C1-3 opcionalmente sustituido con uno o más grupos halo, (iv) -Oalquil C1-3 opcionalmente sustituido con uno o más grupos halo, (v) -Ocicloalquil C3-6, (vi) -CH2OH, (vii) -COOR1, (viii) -CN y (ix) -NR10R11; X se selecciona de -O- y -S-; Y se selecciona de (a) -NR6- CHR7 y -NR8-C(O)- en los que el N en Y está unido al resto heterocíclico de 5 miembros de formula (1) y el C en Y está unido al resto heterocíclico bicíclico de formula (1), (b) -S- y (c) -O-; R1 se selecciona del grupo consistente en - H, alquil C1- 6 y -cicloalquil C3-6; R2 se selecciona del grupo consistente en -H, -OH, -F, -alquil C1-3, -Oalquil C1-3 y -OC(O)-alquil C1-3; R3 se selecciona del grupo consistente en -H, -alquil C1-6, -alquil C1-6 sustituido con uno o más grupos fluoro, -alquil C1-6 sustituido con R9, -alquenil C2-6, -cicloalquil C3-6, -cicloalquenil C5-7 y -Z; R4 se selecciona del grupo consistente en -H, -alquil C1-6, -alquil C1-6 sustituido con uno o más grupos fluoro, -alquil C1-6 sustituido con R9, -alquenil C2-6, - cicloalquil C3-6, -cicloalquenil C5-7 y -Z; o R3 y R4 representan conjuntamente oxo; o R3 y R4 se articulan conjuntamente con el C al cual están unidos para formar un anillo seleccionado del grupo consistente en un anillo - cicloalquil C3-6 y un anillo -cicloalquenil C5-7, dado que cuando R3 y R4 se articulan conjuntamente con el C al cual están unidos para formar un anillo -cicloalquenil C5-7, no hay doble enlace en la posicion C-1 en el anillo; o R2, R3 y R4 se articulan conjuntamente con el C al cual están unidos para formar un anillo cicloalquenilo seleccionado de las formulas (2), R5 está ausente o es un sustituyente seleccionado a partir del grupo consistente en -alquil C1-6, cicloalquil C3-6 y halo; R6 se selecciona del grupo consistente en (a) -H, (b) -alquil C1-4, (c) -C(O)alquil C1-4 y (d) -C(O)fenil opcionalmente sustituido con -alquil C1-4; R7 se selecciona del grupo consistente en (a) -h, (b) alquilo C1-4, (c) -cicloalquil C3-6 y (d) fenilo opcionalmente mono- o di- sustituido con un sustituyente independientemente seleccionado en cada aparicion del grupo consistente en -alquil C1-4, -F y -Cl, y (e) un anillo aromático de 5 miembros que contiene (i) uno o más átomos de C, (ii) un heteroátomo seleccionado a partir de O y S; y (iii) 0, 1, 2 o 3 átomos de N; R8 se selecciona del grupo consistente en -H y -alquil C1-4; R9 se selecciona del grupo consistente en -COOR1, -C(O)H, -CN, -CR1R1OH, -OR1, -S-alquil C1-6 y -S-cicloalquil C3-6; R10 se selecciona del grupo consistente en -H, - alquil C1-6, -cicloalquil C3-6 y -COOR1; R11 se selecciona del grupo consistente en -H, -alquil C1-6 y -cicloalquil C3-6; y Z se selecciona del grupo consistente en (a) un anillo aromático de 5 miembros que contiene (i) uno o más átomos de C, (ii) un heteroátomo seleccionado a partir de O y S, y (iii) 0, 1, 2 o 3 átomos de N; (b) un anillo aromático de 5 miembros que contiene uno o más átomos de C y de uno a cuatro átomos de N, (c) un anillo aromático de 6 miembros que contiene átomos de C y 1, 2 o 3 átomos de N; (d) fenilo, y (e) -CH2-fenil y -CH2-dioxolanil, y en el que Z está opcionalmente mono- o di-sustituida con un sustituyente independientemente seleccionado en cada aparicion del grupo consistente en (i) - F, (ii) -Cl, (iii) -alquil C1-3 opcionalmente sustituido con uno o más grupos halo que incluye por ejemplo -CF3, (iv) -Oalquil C1-3 opcionalmente sustituido con uno o más grupos halo, (v) -Ocicloalquil C3-6, (vi) -CH2OH, (vii) -COOR1, (viii) -CN y (ix) -NR10R11.
ARP060100953A 2005-03-23 2006-03-13 Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. AR055041A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66431705P 2005-03-23 2005-03-23

Publications (1)

Publication Number Publication Date
AR055041A1 true AR055041A1 (es) 2007-08-01

Family

ID=37023348

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100953A AR055041A1 (es) 2005-03-23 2006-03-13 Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.

Country Status (26)

Country Link
US (3) US7553973B2 (es)
EP (1) EP1869031B1 (es)
JP (2) JP4109316B1 (es)
KR (1) KR20070113259A (es)
CN (2) CN101146802A (es)
AR (1) AR055041A1 (es)
AU (1) AU2006227524B2 (es)
BR (1) BRPI0609687A2 (es)
CA (1) CA2600727C (es)
CR (1) CR9442A (es)
DO (1) DOP2006000069A (es)
EA (1) EA012704B1 (es)
ES (1) ES2394179T3 (es)
GT (1) GT200600117A (es)
IL (1) IL185724A0 (es)
MA (1) MA29398B1 (es)
MX (1) MX2007011638A (es)
MY (1) MY142105A (es)
NI (1) NI200700242A (es)
NO (1) NO20075384L (es)
PA (1) PA8667201A1 (es)
PE (1) PE20061328A1 (es)
TN (1) TNSN07348A1 (es)
TW (1) TWI321130B (es)
WO (1) WO2006099735A1 (es)
ZA (1) ZA200707385B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
EP1934205A4 (en) * 2005-10-05 2010-06-02 Merck Frosst Canada Ltd SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUCOTRIENE BIOSYNTHESIS
AR065093A1 (es) * 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
AR068498A1 (es) * 2007-09-27 2009-11-18 Merck & Co Inc Compuestos de oxadiazol para inhibicion de biosintesis de leucotrienos
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
SG191041A1 (en) 2010-12-07 2013-08-30 Amira Pharmaceuticals Inc Polycyclic lpa1 antagonist and uses thereof
PH12013501136A1 (en) 2010-12-07 2013-07-08 Amira Pharmaceuticals Inc Lysophosphatidic acid receptor antagonists and uses thereof
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2014031586A2 (en) * 2012-08-20 2014-02-27 Tallikut Pharmaceuticals, Inc. Methods for treating cardiovascular diseases
CN102924442B (zh) * 2012-11-15 2014-10-29 沈阳药科大学 含有噻唑环的色满类化合物及其类似物和医药用途
CN103304556B (zh) * 2013-06-21 2016-06-01 天津药物研究院有限公司 含有苯并吡喃的希夫碱类化合物、其制备方法和用途
ES2838977T3 (es) 2015-03-06 2021-07-02 Pharmakea Inc Inhibidores de la lisil oxidasa fluorada tipo 2 y usos de los mismos
KR102130783B1 (ko) * 2015-09-24 2020-07-08 구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드 4-치환된 쿠마린 유도체 및 이의 제조 방법 및 용도
CN117180280A (zh) 2016-09-07 2023-12-08 法玛克亚公司 赖氨酰氧化酶样2抑制剂的用途
AU2017324445A1 (en) 2016-09-07 2019-04-11 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
CN108658962B (zh) * 2017-03-30 2021-10-01 复旦大学 3-取代香豆素呋咱衍生物及其在制备抗多药耐药肿瘤药物中的用途
CN111116506B (zh) * 2019-12-31 2024-03-08 浙江大学衢州研究院 一种芳巯基二唑类衍生物的合成方法
CN113149979B (zh) * 2021-03-05 2022-11-25 朗捷睿(苏州)生物科技有限公司 一种8-(苯并噻唑酰胺)取代香豆素类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3834860A1 (de) * 1988-10-13 1990-04-19 Basf Ag Heterocyclisch substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
DE4235603A1 (de) * 1992-10-22 1994-04-28 Basf Ag Arylalkoxythiocumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel
US5424320A (en) * 1993-06-23 1995-06-13 Merck Frosst Canada, Inc. Heteroaryl coumarins as inhibitors of leukotriene biosynthesis
EP0650964A1 (en) 1993-11-02 1995-05-03 Duphar International Research B.V 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives
US5552437A (en) * 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5576338A (en) * 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
US6265421B1 (en) * 1997-06-25 2001-07-24 Orion Corporation Phospholamban inhibitors and a method for increasing coronary flow
US6538022B1 (en) * 1997-09-24 2003-03-25 Orion Corporation Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
US5968959A (en) * 1997-12-12 1999-10-19 Orion Corporation Method for the prevention and treatment of stunned myocardium
NZ523550A (en) * 2000-07-13 2004-05-28 Takeda Chemical Industries Ltd Lipid-rich plaque inhibitors
WO2002047723A1 (fr) 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicamenteuses presentant une meilleure hydrosolubilite
WO2004014388A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
AU2004245146B2 (en) * 2003-06-11 2010-01-21 Merck Frosst Canada Ltd 7-(1,3-thiazol-2-yl)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.

Also Published As

Publication number Publication date
TW200700414A (en) 2007-01-01
AU2006227524A1 (en) 2006-09-28
EP1869031B1 (en) 2012-08-08
JP4109316B1 (ja) 2008-07-02
MY142105A (en) 2010-09-15
NI200700242A (es) 2008-05-13
JP5207711B2 (ja) 2013-06-12
US20090030048A1 (en) 2009-01-29
MA29398B1 (fr) 2008-04-01
IL185724A0 (en) 2008-01-06
EA200702058A1 (ru) 2008-02-28
CN101146802A (zh) 2008-03-19
EP1869031A1 (en) 2007-12-26
CN102627638A (zh) 2012-08-08
US20090227638A1 (en) 2009-09-10
CA2600727A1 (en) 2006-09-28
ZA200707385B (en) 2010-01-27
BRPI0609687A2 (pt) 2010-04-20
US7553973B2 (en) 2009-06-30
WO2006099735A1 (en) 2006-09-28
GT200600117A (es) 2007-01-19
TWI321130B (en) 2010-03-01
TNSN07348A1 (en) 2008-12-31
PA8667201A1 (es) 2006-10-13
MX2007011638A (es) 2007-11-14
EA012704B1 (ru) 2009-12-30
DOP2006000069A (es) 2006-09-30
KR20070113259A (ko) 2007-11-28
PE20061328A1 (es) 2007-01-13
JP2008101010A (ja) 2008-05-01
ES2394179T3 (es) 2013-01-23
AU2006227524B2 (en) 2011-06-30
CA2600727C (en) 2011-06-14
NO20075384L (no) 2007-11-30
US20070149579A1 (en) 2007-06-28
EP1869031A4 (en) 2011-02-09
JP2008533179A (ja) 2008-08-21
CR9442A (es) 2008-01-21

Similar Documents

Publication Publication Date Title
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR066153A1 (es) Derivados de piperidina / piperazina
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
AR048537A1 (es) Derivados de nucleosidos para tratar infecciones por virus de hepatitis c.
AR016523A1 (es) Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR055015A1 (es) Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos.
AR036093A1 (es) Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
AR066911A1 (es) Derivados de piperidina / piperazina
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
PE20210398A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
EA200801828A3 (ru) Соединения 1,2,4,5- тетрагидро-3н-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
AR066020A1 (es) Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1.
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
AR065280A1 (es) Agentes antiparasitarios
AR064760A1 (es) Derivados de diazol como inhibidores de la eg-5
AR063119A1 (es) Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1)
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal